Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, Fissette L, David MP, Maréchal C, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Feldman RG, et al. Among authors: van der wielen m. Clin Infect Dis. 2024 Jan 25;78(1):202-209. doi: 10.1093/cid/ciad471. Clin Infect Dis. 2024. PMID: 37698366 Free PMC article.
Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, Hoet B, Stoffel M. Heron L, et al. Among authors: van damme p, van der wielen m. Vaccine. 2007 Apr 12;25(15):2817-22. doi: 10.1016/j.vaccine.2006.12.021. Epub 2006 Dec 29. Vaccine. 2007. PMID: 17276552 Clinical Trial.
Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.
Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM. Memish ZA, et al. Among authors: van der wielen m. Pediatr Infect Dis J. 2011 Apr;30(4):e56-62. doi: 10.1097/INF.0b013e31820e6e02. Pediatr Infect Dis J. 2011. PMID: 21278617 Clinical Trial.
Second diphtheria booster in adults raises immunity to 92%.
Vellinga A, Van Damme P, Joosens E, van Der Wielen M, Goossens H. Vellinga A, et al. Among authors: van damme p, van der wielen m. BMJ. 2001 Dec 1;323(7324):1308. doi: 10.1136/bmj.323.7324.1308. BMJ. 2001. PMID: 11731400 Free PMC article. No abstract available.
Combined hepatitis A and B vaccine in elderly.
Van Damme P, Van Herck K, Van der Wielen M. Van Damme P, et al. Among authors: van der wielen m, van herck k. Vaccine. 2004 Jan 2;22(3-4):303-4. doi: 10.1016/j.vaccine.2003.08.011. Vaccine. 2004. PMID: 14670309 No abstract available.
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L, Schwarz TF, Kim KH, Kim YK, Behre U, Cha SH, Jo DS, Lee J, Lee JS, Cheuvart B, Jastorff A, Van der Wielen M. Rivera L, et al. Among authors: van der wielen m. Vaccine. 2018 Jul 25;36(31):4750-4758. doi: 10.1016/j.vaccine.2018.04.034. Epub 2018 Jun 28. Vaccine. 2018. PMID: 29960800 Free article. Clinical Trial.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. Borja-Tabora CFC, et al. Among authors: van der wielen m. BMC Infect Dis. 2020 Jun 18;20(1):426. doi: 10.1186/s12879-020-05104-5. BMC Infect Dis. 2020. PMID: 32552685 Free PMC article. Clinical Trial.
94 results